Durability of Nevirapine-Based Antiretroviral Regimen

• Status: Completed
• Trial end date: 2010-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Although nevirapine is used as an alternative to efavirenz for initial regimen in developed countries, nevirapine has still been a key antiretroviral drug in many resource-limited countries including Thailand due to its accessibility and affordability. In addition, a component of stavudine and lamivudine is still widely used as a backbone in the antiretroviral regimen in this setting.To date, data on the durability of a regimen of stavudine, lamivudine and nevirapine are very limited, particularly from the resource-limited settings.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bamrasnaradura Infectious Diseases Institute
• Treatments: Nevirapine

Criteria

Inclusion Criteria:

• HIV-infected individuals ≥15 years of age

• CD4 cell count <350 cells/mm3

• Willing to participate and give consent form

Exclusion Criteria:

• previous antiretroviral therapy

• pregnancy

• receiving a medication that has drug-drug interactions with NVP or RFP

• aspartate aminotransferase (AST) and alanine aminotransferase (ALT) >5 times of upper limit of normal range